​

Monte Rosa Therapeutics Ownership | Who Owns Monte Rosa Therapeutics?

OverviewForecastRevenueFinancialsChart

Monte Rosa Therapeutics Ownership Summary

Monte Rosa Therapeutics is owned by 142.23% institutional investors, 0.56% insiders. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 13.52% of GLUE shares. Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund, with 3.02% of its assets in Monte Rosa Therapeutics shares.

GLUE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMonte Rosa Therapeutics142.23%0.56%-42.79%
SectorHealthcare Stocks 50.59%12.40%37.01%
IndustryBiotech Stocks 49.10%12.14%38.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Price t rowe associates inc /md/8.86M13.52%$214.44M
Nea management company7.69M11.74%$186.15M
Blackrock funding, inc. /de6.84M10.44%$165.60M
Tcg crossover management4.62M7.05%$111.86M
Vestal point capital, lp4.60M7.02%$111.32M
Bvf inc/il4.46M6.81%$107.95M
Baker bros. advisors lp4.35M6.63%$105.17M
State street3.73M5.69%$90.30M
Suvretta capital management3.55M5.42%$85.90M
Vanguard capital management3.41M5.21%$82.59M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Versant venture management3.18M47.34%$76.97M
Nea management company7.69M11.72%$186.15M
Aisling capital management lp1.56M7.98%$37.65M
Boone capital management615.29K3.48%$14.89M
Silverarc capital management1.11M2.79%$26.82M
Bvf inc/il4.46M2.76%$107.95M
Tcg crossover management4.62M2.69%$111.86M
Vestal point capital, lp4.60M2.60%$111.32M
Braidwell lp2.45M2.19%$59.33M
Exome asset management137.12K2.05%$3.32M

Top Buyers

HolderShares% AssetsChange
Price t rowe associates inc /md/8.86M0.02%2.14M
Blackrock funding, inc. /de6.84M0.00%1.21M
Vestal point capital, lp4.60M2.60%996.53K
Woodline partners lp962.88K0.07%888.39K
Opaleye management745.00K1.63%745.00K

Top Sellers

HolderShares% AssetsChange
Avoro capital advisors---3.73M
American century companies1.62M0.02%-1.19M
Silverarc capital management1.11M2.79%-893.75K
Braidwell lp2.45M2.19%-755.01K
Suvretta capital management3.55M1.57%-677.27K

New Positions

HolderShares% AssetsChangeValue
Opaleye management745.00K1.63%745.00K$18.03M
Janus henderson group685.93K0.01%685.93K$11.29M
First trust advisors lp647.80K0.01%647.80K$15.68M
Sixth street partners management company616.31K0.00%616.31K$14.91M
Boone capital management615.29K3.48%615.29K$14.89M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Clearstead advisors-8.00
Jpl wealth management-8.00
Turning point benefit group-14.00
Capital performance advisors llp-29.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262002.56%93,220,1937.22%1420.81%110-17.91%5940.48%
Mar 31, 202618913.86%86,330,08433.91%1031.70%13229.41%415.13%
Dec 31, 202565-51.13%12,491,437-79.19%150.28%46-24.59%9-77.50%
Sep 30, 202547-59.83%19,971,709-67.89%240.42%21-72.37%16-11.11%
Jun 30, 20251167.41%62,164,3354.44%751.44%7570.45%18-60.87%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Morn Total Stk Mkt Idx Investor2.55M3.02%249.40K
Vanguard Total Stock Mkt Idx Inv2.55M3.02%249.40K
Vanguard MStar Total Stk Mkt Idx Invest2.56M3.00%10.25K
T. Rowe Price New Horizons2.23M2.64%246.60K
US Small-Cap Growth II Equity Comp2.23M2.64%245.71K
State Street® SPDR® S&P® Biotech ETF2.08M2.44%4.78K
iShares Russell 2000 ETF1.89M2.21%-33.50K
HBM Healthcare Investments AG Ord1.82M2.16%-
T. Rowe Price Health Sciences1.82M2.16%-112.10K
T. Rowe Price Integrated US SmCapGrEq1.38M1.63%810.00K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 16, 2026Warmuth Markus President & CEOSell$220.22K
Jul 15, 2026Champoux Jennifer Chief Operating OfficerSell$101.73K
Jul 06, 2026Townson Sharon Chief Scientific OfficerSell$130.20K
Jul 06, 2026Townson Sharon Chief Scientific OfficerSell$9.65K
Jun 30, 2026Janku Filip Chief Medical OfficerSell$132.47K

Insider Transactions Trends

DateBuySell
2026 Q3-4
2026 Q2-18
2026 Q1-14
2025 Q2-1
2025 Q11-

GLUE Ownership FAQ

Who Owns Monte Rosa Therapeutics?

Monte Rosa Therapeutics shareholders are primarily institutional investors at 142.23%, followed by 0.56% insiders and -42.79% retail investors. The average institutional ownership in Monte Rosa Therapeutics's industry, Biotech Stocks , is 49.10%, which Monte Rosa Therapeutics exceeds.

Who owns the most shares of Monte Rosa Therapeutics?

Monte Rosa Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (8.86M shares, 13.52%), Nea management company (7.69M shares, 11.74%), and Blackrock funding, inc. /de (6.84M shares, 10.44%). Together, they hold 35.70% of Monte Rosa Therapeutics’s total shares outstanding.

Does Blackrock own Monte Rosa Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Monte Rosa Therapeutics.

Who is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is Monte Rosa Therapeutics’s biggest shareholder by percentage of total assets invested, with 47.34% of its assets in 3.18M Monte Rosa Therapeutics shares, valued at 76.97M$.

Who is the top mutual fund holder of Monte Rosa Therapeutics shares?

Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund holder of Monte Rosa Therapeutics shares, with 3.02% of its total shares outstanding invested in 2.55M Monte Rosa Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools